candidate 13 / VeraVerse, Yonsei University, CKP Therap - LARVOL DELTA

Yonsei researchers find novel drug candidate to treat clinically refractory cancers (Korea Biomedical Review) - "Korean researchers said they have discovered a method to treat cancers that do not respond to existing anticancer drugs....The research team developed a PMCA inhibitor (candidate 13) and confirmed its therapeutic effect with the standard anticancer drug in animal models....When the combination of oxaliplatin and candidate 13 was administered to a tumor that was initially 200 mm3, it was 254.32 mm3 after 20 days, 288.4 mm3 after 30 days, and 283.44 mm3 after 40 days....The research team applied for domestic and international patents based on the latest study."

New molecule • Preclinical • Oncology